サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791537

生物製剤受託開発の世界市場

Biologics Contract Development

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
生物製剤受託開発の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生物製剤受託開発の世界市場は2030年までに140億米ドルに達する見込み

2024年に91億米ドルと推定される生物製剤受託開発の世界市場は、2024年から2030年にかけてCAGR 7.5%で成長し、2030年には140億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである哺乳類ソースは、CAGR 7.2%を記録し、分析期間終了時には66億米ドルに達すると予想されます。微生物源セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は24億米ドルと推定、中国はCAGR 7.3％で成長予測

米国の生物製剤受託開発市場は、2024年に24億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに22億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.9％と6.4％と予測されています。欧州では、ドイツがCAGR約6.1%で成長すると予測されています。

世界の生物製剤受託開発市場- 主要動向と促進要因のまとめ

生物製剤受託開発がバイオ医薬品業界で勢いを増す理由とは？

生物製剤受託開発は、バイオテクノロジー企業や大手製薬会社が創薬を加速し、製品開発を合理化し、製造プロセスを最適化することを可能にする、製薬エコシステムにとって不可欠な存在となっています。モノクローナル抗体、遺伝子治療薬、組換えタンパク質などの生物学的製剤の複雑化に伴い、企業は生物学的製剤開発の主要な段階を、専門知識、規制遵守、高度な製造能力を提供する専門の開発業務受託機関（CDO）にアウトソーシングする傾向が強まっています。生物製剤の需要は、がん、自己免疫疾患、希少遺伝子疾患などの慢性疾患の治療に有効であることから急増しています。しかし、生物学的製剤の開発には高いコストと技術的な複雑さが伴うため、社内の研究開発チームにとっては大きな課題となっています。その結果、製薬会社はCDOの専門知識を活用し、初期段階の研究、細胞株開発、プロセスの最適化、分析試験を実施することで、コストを削減し、市場投入までの時間を短縮しています。バイオシミラーや個別化医療の台頭により、効率的な開発業務受託のニーズは今後数年で大幅に高まると予想されます。

技術の進歩はどのように生物製剤受託開発を強化しているか？

人工知能（AI）、自動化、シングルユースバイオプロセシングシステムなどの最先端技術の統合は、生物製剤受託開発を変革し、効率性、拡張性、品質保証を向上させています。AIを活用した創薬プラットフォームは、膨大なデータセットを分析し、分子間相互作用を高精度で予測することで、治療薬候補の迅速な同定を可能にしています。これにより、生物学的製剤開発の初期段階が加速し、前臨床研究に要する時間が短縮されます。さらに、シングルユース・バイオリアクターとモジュール式生産設備の採用により、生物学的製剤製造の柔軟性とコスト効率が向上しています。これらの技術革新により、開発業務受託機関は変化する顧客の要求に迅速に対応し、少量生産や個別化された生物学的製剤の生産効率を向上させることができます。さらに、細胞株工学やCRISPRのような遺伝子編集技術の進歩は、生物学的製剤候補の生産性と安定性を向上させ、より高い収率と治療効果の向上を確実なものにしています。生物学的治療がより専門化・複雑化するにつれ、技術革新は開発受託サービスの進化を促し続けると思われます。

生物製剤受託開発の成長を促進する市場動向とは？

生物製剤受託開発市場を形成する最も重要な動向の一つは、バイオシミラーと新規生物学的製剤の需要の増加です。ブロックバスター生物製剤の特許が切れるにつれ、製薬会社は市場シェアを獲得し、より安価な治療オプションを提供するためにバイオシミラーの開発に注力しています。開発業務受託機関は、分析特性、生物学的同等性試験、法規制遵守の専門知識を提供することで、バイオシミラー開発を促進する上で重要な役割を果たしています。もう一つの主な動向は、個別化医療や細胞・遺伝子治療開発へのシフトです。ゲノム研究と精密医療の進歩に伴い、製薬会社は個々の患者に合わせた生物学的治療に投資しています。このシフトは、高度な細胞療法、ウイルスベクター生産、カスタマイズされた生物学的製剤に特化した受託開発サービスの需要を促進しています。さらに、規制当局は革新的な生物学的製剤に合理化された承認経路を導入しており、開発業務受託機関との戦略的アウトソーシング・パートナーシップを通じて開発期間を短縮するよう企業に促しています。

生物製剤受託開発市場の主な成長促進要因は？

生物製剤受託開発市場の成長は、生物学的製剤に対する需要の増加、バイオシミラーへの投資の増加、生物学的製剤製造の複雑化など、いくつかの要因によってもたらされます。製薬企業がコストの最適化と医薬品開発期間の短縮を目指す中、開発業務受託機関の果たす役割はますます重要になっています。特に新興国市場における生物製剤製造インフラの拡大は、バイオテクノロジー企業や小規模製薬会社にコスト効率の高い開発ソリューションを提供することで、市場開拓をさらに後押ししています。さらに、自動化、AI、高度なバイオプロセス技術の採用が進むことで、生物製剤受託開発サービスの効率性と拡張性が高まっています。規制当局が生物製剤とバイオシミラーの拡大を支援し続ける中、開発業務受託機関は持続的な成長を遂げ、将来のバイオ医薬品イノベーションにおける重要なパートナーとしての地位を強化すると予想されます。

セグメント

ソース（哺乳類ソース、微生物ソース、その他ソース）;サービス（プロセス開発サービス、細胞株開発サービス、その他サービス）;インディケーション（がん領域、免疫疾患領域、循環器疾患領域、血液疾患領域、その他領域）

調査対象企業の例

  • Biovian Oy
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Celonic AG
  • Charles River Laboratories
  • FUJIFILM Corporation
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group
  • LOTTE BIOLOGICS
  • Mabxience Holding S.L.
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Samsung Biologics Co., Ltd.
  • Scorpius BioManufacturing
  • Syngene International Ltd.
  • WuXi Biologics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29589

Global Biologics Contract Development Market to Reach US$14.0 Billion by 2030

The global market for Biologics Contract Development estimated at US$9.1 Billion in the year 2024, is expected to reach US$14.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Mammalian Source, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Microbial Source segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 7.3% CAGR

The Biologics Contract Development market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Biologics Contract Development Market - Key Trends & Drivers Summarized

Why Is Biologics Contract Development Gaining Momentum in the Biopharmaceutical Industry?

Biologics contract development has become an essential part of the pharmaceutical ecosystem, enabling biotech firms and large pharmaceutical companies to accelerate drug discovery, streamline product development, and optimize manufacturing processes. With the increasing complexity of biologic drugs such as monoclonal antibodies, gene therapies, and recombinant proteins, companies are increasingly outsourcing key stages of biologics development to specialized contract development organizations (CDOs) that offer expertise, regulatory compliance, and advanced manufacturing capabilities. The demand for biologics is surging due to their effectiveness in treating chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. However, the high costs and technical complexities associated with biologic drug development pose significant challenges for in-house research and development teams. As a result, pharmaceutical companies are leveraging the expertise of CDOs to conduct early-stage research, cell line development, process optimization, and analytical testing, thereby reducing costs and accelerating time-to-market. With the rise of biosimilars and personalized medicine, the need for efficient contract development services is expected to grow substantially in the coming years.

How Are Technological Advancements Enhancing Biologics Contract Development?

The integration of cutting-edge technologies such as artificial intelligence (AI), automation, and single-use bioprocessing systems is transforming biologics contract development, improving efficiency, scalability, and quality assurance. AI-driven drug discovery platforms are enabling faster identification of therapeutic candidates by analyzing vast datasets and predicting molecular interactions with high accuracy. This accelerates the initial stages of biologic development and reduces the time required for preclinical research. Additionally, the adoption of single-use bioreactors and modular production facilities is enhancing the flexibility and cost-effectiveness of biologic manufacturing. These innovations allow contract development organizations to quickly adapt to changing client requirements and improve production efficiency for small-batch and personalized biologic drugs. Moreover, advancements in cell line engineering and gene editing techniques such as CRISPR are improving the productivity and stability of biologic drug candidates, ensuring higher yields and improved therapeutic efficacy. As biologic therapies become more specialized and complex, technological innovation will continue to drive the evolution of contract development services.

What Market Trends Are Driving the Growth of Biologics Contract Development?

One of the most significant trends shaping the biologics contract development market is the increasing demand for biosimilars and novel biologic therapies. As patents for blockbuster biologics expire, pharmaceutical companies are focusing on developing biosimilars to capture market share and provide more affordable treatment options. Contract development organizations play a crucial role in facilitating biosimilar development by providing expertise in analytical characterization, bioequivalence testing, and regulatory compliance. Another key trend is the shift toward personalized medicine and cell and gene therapy development. With advancements in genomic research and precision medicine, pharmaceutical companies are investing in biologic therapies tailored to individual patients. This shift is driving the demand for contract development services that specialize in advanced cell therapies, viral vector production, and customized biologic formulations. Additionally, regulatory agencies are introducing streamlined approval pathways for innovative biologics, encouraging companies to accelerate their development timelines through strategic outsourcing partnerships with contract development organizations.

What Are the Key Growth Drivers for the Biologics Contract Development Market?

The growth in the Biologics Contract Development market is driven by several factors, including increasing demand for biologic drugs, rising investment in biosimilars, and the growing complexity of biologic manufacturing. As pharmaceutical companies seek to optimize costs and accelerate drug development timelines, contract development organizations are playing an increasingly critical role in the industry. The expansion of biologics manufacturing infrastructure, particularly in emerging markets, is further propelling market growth by providing cost-effective development solutions to biotech firms and small pharmaceutical companies. Additionally, the increasing adoption of automation, AI, and advanced bioprocessing technologies is enhancing the efficiency and scalability of biologics contract development services. As regulatory agencies continue to support the expansion of biologics and biosimilars, contract development organizations are expected to see sustained growth, reinforcing their position as key partners in the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Biologics Contract Development market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Source (Mammalian Source, Microbial Source, Other Sources); Service (Process Development Service, Cell Line Development Service, Other Services); Indication (Oncology Indication, Immunological Disorders Indication, Cardiovascular Disorders Indication, Hematological Disorders Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Biovian Oy
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Celonic AG
  • Charles River Laboratories
  • FUJIFILM Corporation
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group
  • LOTTE BIOLOGICS
  • Mabxience Holding S.L.
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Samsung Biologics Co., Ltd.
  • Scorpius BioManufacturing
  • Syngene International Ltd.
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biologics Contract Development - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rapid Expansion of Biopharmaceutical Pipelines Throws the Spotlight on Outsourced Biologics Development Services
    • OEM Investment in Monoclonal Antibodies, ADCs, and Fusion Proteins Drives Demand for Specialized CDMO Expertise
    • Surge in Venture Capital Funding for Biotech Startups Propels Early-Stage Biologics Development Outsourcing
    • Increased Complexity of Biologics Manufacturing Strengthens Business Case for End-to-End CDMO Partnerships
    • Rising Adoption of Cell and Gene Therapies Spurs CDMO Capability Expansion in Viral Vector and Plasmid Development
    • OEM Focus on Modular and Flexible Development Platforms Enhances Speed-to-IND and Speed-to-BLA Timelines
    • Growth in Biosimilars and Biobetters Development Expands Demand for Regulatory-Compliant Development Support
    • Regulatory Emphasis on CMC Documentation and QbD Principles Drives Demand for Early Integration Services
    • Shift Toward Integrated Drug Discovery to Manufacturing Models Fuels Strategic CDMO Consolidation
    • Emergence of Continuous Bioprocessing and PAT Integration Spurs Innovation in Process Development Offerings
    • OEM Collaboration With CROs and AI Platforms Enhances Data-Driven Molecule Optimization
    • Surging Interest in Dual-Target and Bispecific Biologics Supports Demand for High-Throughput Screening Platforms
    • Globalization of Biotech Innovation Clusters Promotes Cross-Border Development Partnerships
    • OEM Development of Standardized, Platform-Based Expression Systems Supports Scalability and IP Protection
    • Increased Investment in High-Yield Cell Line Development Services Propels Productivity Optimization
    • Emphasis on Speed, Cost Containment, and Risk Sharing Drives Growth of Hybrid FFS/FTE Development Models
    • Demand for Clinical-Grade and Preclinical Material Supply Accelerates Multi-Site Development Capacity Expansion
    • Expansion of Biologics in Rare Disease and Orphan Drug Portfolios Fuels Need for Flexible CDMO Capabilities
    • Growth in Personalized Biologics and Companion Diagnostics Enhances Demand for Integrated Development Services
    • Regulatory Convergence in Global Markets Promotes Use of CDMOs for Multi-Jurisdiction Filing Preparation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biologics Contract Development Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biologics Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Biologics Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Microbial Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Process Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Process Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cell Line Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cell Line Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Immunological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Immunological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Cardiovascular Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hematological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hematological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • JAPAN
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • CHINA
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • EUROPE
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Biologics Contract Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • FRANCE
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • GERMANY
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030

IV. COMPETITION